Background: Coeliac disease (CD) is an autoimmune disease that causes an inappropriate 3 inflammatory immune response to dietary gluten. Telomere length is a marker of biological 4 ageing and is reduced in several autoimmune conditions. This observational study measured 5 salivary telomere length (TL) in gluten-free diet (GFD) treated CD individuals to determine if 6 CD, and length of time on a GFD, is associated with salivary TL.
Introduction 23
Coeliac disease (CD) is an autoimmune disorder characterised by damage to the small 24 intestine in genetically predisposed individuals [1] . In individuals with CD, exposure to dietary 25 gluten triggers an immune response producing oxidative stress, inflammation and histological 26 changes within the intestinal mucosa [2] [3] [4] . The only treatment is a lifelong gluten free diet 27 (GFD) which, results in remission of immune mediated intestinal damage and symptom 28 resolution [4] . 29 Telomeres are repetitive DNA sequences that cap the end of chromosomes, protecting them 30 from degradation and chromosome fusion [5] . These structures progressively shorten with 31 each cell division, until they reach a critical length and induce cell senescence and/or cell 32 death. Telomere length (TL) is therefore widely considered as a marker of biological ageing. 33 Shorter telomeres are associated with states of inflammation and oxidative stress, where 34 progressive cell damage results in greater cell turnover, and free radical mediated damage 35 results in 'clipping' of telomere DNA during each cycle of division [6] [7] [8] . The effects of 36 inflammation and oxidative stress on TL have been shown to be reversible, with length 37 gradually recovering when these stressors are removed [9] . 38 Shorter TL have been associated with autoimmune conditions, asthma, and depression [10-39 12]. In CD, shorter TL have been reported in small intestinal biopsy samples and peripheral 40 blood lymphocytes of individuals with CD compared to healthy controls [13] . However, these 41 studies measured TL in individuals with active or untreated CD, that is, in individuals 42 consuming a gluten-containing diet. No studies have investigated whether TL can recover 43 after treatment of CD with a GFD. The aim of this study was to determine whether salivary TL 44 differed between CD individuals currently on a GFD and age-matched healthy controls in a 45 population of individuals under 35 years of age. This study also aimed to determine whether 46 the length of time on a GFD was associated with TL recovery in individuals with CD. 49 Recruitment was carried out between April 2014 and December 2016. Individuals were 50 recruited from the gastroenterology clinic at Campbelltown Hospital, NSW, and from the 51 general population at the 2014, 2015 and 2016 Gluten-Free Expos in Sydney and Melbourne, 52 Australia. Following written informed consent, individuals were asked questions regarding 53 their health and disease status, as previously described [14] . Saliva samples were collected 54 from all participants using the Oragene DNA OG500 self-collection kits (DNA Genotek, 55 Canada). This study was approved by the Western Sydney University Research Ethics 56 Committee (approval number H10513) and was carried out in accordance with the ethical 57 standards laid down in the 1964 Declaration of Helsinki and its later amendments.
47

Methods
48
Participant recruitment and inclusion criteria
58
Only individuals between the age of 18 and 35 at the time of recruitment were included in the 59 study. Individuals were defined as having CD if they fulfilled the following criteria: had been 60 diagnosed with CD via duodenal biopsy by a gastrointestinal specialist; were currently on a 61 GFD; and carried at least one HLA-DQ2 or HLA-DQ8 haplotype. Endoscopy reports were 62 obtained for a subset of CD participants to verify CD histology and confirm their CD status.
63
Individuals were classified as non-affected controls if they reported not having CD or CD 64 associated symptoms and were not on a GFD. TaqMan SNP genotyping assays as previously described [16] .
84
Measurement of relative telomere lengths 85 Relative telomere length in saliva was measured using quantitative PCR as previously 86 described [17, 18] . This method expresses telomere length as a ratio (T/S) of telomere repeat 87 copy number (T) to haemoglobin subunit beta (HBB) single copy gene (S) within each sample. Prior to analysis, T/S ratio values were transformed into natural logarithms to obtain a 96 Gaussian distribution. Multinomial logistic regression was used to determine if there were 97 significant differences in demographic and lifestyle factors between the GFD ≤3yrs CD 98 individuals and unaffected controls, and the GFD >3yrs CD individuals and unaffected 99 controls. Generalised linear models (GLZM) was used to compare salivary TL between the 100 CD groups and unaffected controls, and between the GFD ≤3yrs CD and GFD >3yrs CD, 101 adjusting for age. P values <0.05 were considered statistically significant. All analysis was 102 performed using the IBM SPSS statistics software (version 24).
104
Results and discussion 105 A total of 79 individuals, 52 CD and 27 non-affected controls were included in the study (Fig   106   1 ). These individuals were aged between 18 and 35 years, had not been previously diagnosed 107 with any type of cancer, and reported having never smoked. There were significantly more 108 female participants compared to males (88.6% vs 11.4%). There were no significant 109 differences in age, BMI, alcohol consumption or presence of associated conditions between 110 individuals with CD and non-affected controls (Table 1) . Age, sex, BMI, alcohol consumption, 111 or presence of associated conditions were not associated with salivary TL, however as age is 112 a known predictor of TL, all subsequent analyses were adjusted for age. Stratifying the CD 113 cohort by length of time on a GFD found CD individuals who had commenced a GFD ≤3 years 114 ago had shorter TL when compared to non-affected controls, but this was not significant In individuals with CD gluten ingestion results in intestinal inflammation and villous atrophy, 130 which can be reversed following removal of dietary gluten [2, 3, [20] [21] [22] . Individuals with active 131 CD who are not on a GFD have been reported to have shorter TL when compared to age-132 matched controls in their intestinal mucosa and peripheral blood leukocytes [1, 13] . The 133 current study was conducted in treated CD individuals who were following a GFD. This may 134 explain why no difference in TL between CD individuals and non-affected controls was 135 observed, as TL is known to recover following the removal of inflammation inducing stressors 
144
For individuals who had been undiagnosed for a long period of time or who had experienced 145 severe disease, the cellular damage to their intestinal mucosa can take many years to 146 completely repair, even with a GFD [28, 29] . This may explain why individuals with CD who 147 had commenced a GFD more recently had significantly shorter TL when compared with 148 individuals who have been treated with a GFD for greater than 3 years. It could also explain 149 why we saw a trend for shorter TL in more recently diagnosed CD individuals when compared 150 to controls, while no difference was observed between CD individuals who had been on GFD 151 for greater than 3 years when compared to controls, as TL also required longer periods of time 152 to recover.
153
Undiagnosed CD is also associated with an increased risk of developing small intestinal 154 adenocarcinoma and lymphomas [30] . In individuals with CD, this increased risk has been 155 shown to be reduced with a GFD, with CD individuals treated with a GFD for greater than five prolonged period prior to diagnosis, and therefore the years since diagnosis may not always 166 reflect the length of time that the individual had been living with disease. We attempted to 167 reduce this effect by studying a younger population (<35 years of age) who were less likely to 168 have lived with untreated CD for prolonged periods. This study used saliva instead of intestinal 169 mucosa to measure TL, and our findings may not apply to telomeres measured in other tissues 170 of individuals with CD. However, as untreated CD is characterised by systemic inflammation, 171 and the oral mucosa of CD individuals is known to react to gluten exposure, saliva represents 172 an appropriate and non-invasive tissue source to measure TL.
173
This study measured salivary TL in individuals with treated CD, and non-affected controls. We 174 found no significant difference in salivary TL between individuals with CD and controls. Within 175 the CD cohort, the length of time on a GFD was significantly associated with relative salivary 176 TL, with individuals who had commenced a GFD within the past three years having shorter 177 telomeres compared with individuals who had been treated with a GFD for longer than three 178 years. Treatment of CD with a GFD may assist in the recovery of telomere length, highlighting 179 the importance of early diagnosis and initiation of a GFD to minimise exposure to mucosal 180 damage and telomere attrition. 
